ACS Chem Biol:给力!新型疫苗可有效对抗阿片类药物过量

2016-11-27 MedSci MedSci原创

阿片类药物已成为美国最致命的药物之一,每天有78名美国人因其过量而死亡。现在,来自斯克里普斯研究所(TSRI)的一项新的研究探究了一种新型疫苗,或可降低致命的阿片类药物过量的风险,该研究结果已发表于ACS Chemical Biology。此新的疫苗,称为“氧/水疫苗”,利用了免疫系统识别和中和异物的能力。将其注射至体内,可触发免疫反应,从而靶向并结合阿片类药物分子,将其从血液中清除。该研究中,研

阿片类药物已成为美国最致命的药物之一,每天有78名美国人因其过量而死亡。现在,来自斯克里普斯研究所(TSRI)的一项新的研究探究了一种新型疫苗,或可降低致命的阿片类药物过量的风险,该研究结果已发表于ACS Chemical Biology。

此新的疫苗,称为“氧/水疫苗”,利用了免疫系统识别和中和异物的能力。将其注射至体内,可触发免疫反应,从而靶向并结合阿片类药物分子,将其从血液中清除。

该研究中,研究人员给予小鼠两种常用的阿片类药物——羟考酮和氢可酮,以探究疫苗的效果。

结果研究人员发现,疫苗阻断了阿片类药物的疼痛抑制作用,此外,该疫苗似乎还可以降低阿片类药物的毒性从而降低了小鼠对药物致死性过量的敏感性;然而有些小鼠确实死于阿片类药物的应用,但是疫苗仍然延长了小鼠出现药物中毒的时间。

研究人员发现,在连续60天的研究之后疫苗仍然有效,因此该疫苗的效果或可持续更长的时间。

如果将该疫苗在人类身上同样有效,那么它可成为目前治疗药物成瘾的一种有效的替代药物。

此外,通过减缓阿片类药物的毒性积累时间,疫苗可能会延长在过量服用的情况下的临床援助的时间。

下一步研究中研究人员计划探究疫苗对阿片类药物滥用的有效性,特别是要确定疫苗使用的最佳剂量和注射程序。

原始出处:

Kim D. Janda et al.,An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life, ACS Chemical Biology.17 November 2016.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1767056, encodeId=859c1e67056d0, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Sep 02 01:50:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917348, encodeId=de34191e348e7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 15 19:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032318, encodeId=f2dc20323188b, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jun 09 12:50:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253019, encodeId=6e8b125301954, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279140, encodeId=c42112e91407b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309034, encodeId=3b4f130903438, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1767056, encodeId=859c1e67056d0, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Sep 02 01:50:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917348, encodeId=de34191e348e7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 15 19:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032318, encodeId=f2dc20323188b, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jun 09 12:50:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253019, encodeId=6e8b125301954, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279140, encodeId=c42112e91407b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309034, encodeId=3b4f130903438, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2017-10-15 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1767056, encodeId=859c1e67056d0, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Sep 02 01:50:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917348, encodeId=de34191e348e7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 15 19:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032318, encodeId=f2dc20323188b, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jun 09 12:50:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253019, encodeId=6e8b125301954, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279140, encodeId=c42112e91407b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309034, encodeId=3b4f130903438, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1767056, encodeId=859c1e67056d0, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Sep 02 01:50:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917348, encodeId=de34191e348e7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 15 19:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032318, encodeId=f2dc20323188b, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jun 09 12:50:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253019, encodeId=6e8b125301954, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279140, encodeId=c42112e91407b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309034, encodeId=3b4f130903438, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1767056, encodeId=859c1e67056d0, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Sep 02 01:50:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917348, encodeId=de34191e348e7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 15 19:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032318, encodeId=f2dc20323188b, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jun 09 12:50:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253019, encodeId=6e8b125301954, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279140, encodeId=c42112e91407b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309034, encodeId=3b4f130903438, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-29 yaanren
  6. [GetPortalCommentsPageByObjectIdResponse(id=1767056, encodeId=859c1e67056d0, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Sep 02 01:50:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917348, encodeId=de34191e348e7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 15 19:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032318, encodeId=f2dc20323188b, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jun 09 12:50:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253019, encodeId=6e8b125301954, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279140, encodeId=c42112e91407b, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309034, encodeId=3b4f130903438, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Nov 29 11:50:00 CST 2016, time=2016-11-29, status=1, ipAttribution=)]
    2016-11-29 lhlxtx

相关资讯

疫苗也能对抗食物中毒

大肠杆菌 图片来源:Alamy Stock Photo 你可能没有注意到,当遭受食物中毒或其他感染时,细菌正忙着从你的身体里“盗取”铁元素。许多细菌使用特殊化学制品夺取它们复制时需要的金属。不过,一项新研究显示,这种需要也将导致细菌毁灭。 近日,两个独立研究组首次分别开发出将夺取铁的分子作为靶点的抗感染候选疫苗。该疫苗虽然不能让小鼠预防疾病,但能减缓感染。 在人体

J infect Dis:女性接种HPV疫苗,男性能获益吗?

据来自澳大利亚的研究数据,女性四价HPV疫苗接种计划能大大减少未接种青年男性的病毒流行率。数据表明,男性可能会受益尽可能多只针对女性的高覆盖疫苗接种计划。 墨尔本皇家妇女医院的Dorothy A. Machalek硕士和同事们为了评估女性疫苗接种计划对男性的影响,他们对16至35岁未接种疫苗的异性恋男性进行了研究,根据特定年龄组的阴茎HPV基因型,进行评估。 研究纳入了511名男性。数

Nat Commu:北京微生物流行病研究所等研究提高疫苗有效性

近日,北京微生物流行病研究所等单位的研究人员在《自然—通讯》报告了一种能提高中东呼吸综合征(MERS)疫苗有效性的新方法,该研究也可能有助于设计更有效的对抗一系列病毒性感染的疫苗。 疫苗由可使病人对潜在感染免疫的病毒蛋白组成,但疫苗内部的某些蛋白质并不促成免疫反应,因此降低了接种疫苗的效果。北京微生物流行病研究所病原微生物与生物安全国家重点实验室周育森、美国明尼苏达大学医学院李放及同事,

人类大脑只开发了10%?科学论证25个不靠谱的“医学常识”

导语我们脑子常常被一些固有的医学常识所笼罩,我们觉得他们千真万确,理所当然,宝马哥任其影响我们的生活作息和习惯,实际上它们可能是谣言,看看科学是如何论证的。谣言1:我们的大脑只开发了10%成功学演说家和其他自励领袖们从1907年就开始卖这个鸡汤了,鼓励人们开发更多的潜力。但那些人宣扬的观点并不是主流科学研究的结论。现在,科学家们可以轻易地读取各种脑扫描结果,在任何时间检测脑活动,可以对此谣言付

北京微生物流行病研究所等研究提高疫苗有效性

近日,北京微生物流行病研究所等单位的研究人员在《自然—通讯》报告了一种能提高中东呼吸综合征(MERS)疫苗有效性的新方法,该研究也可能有助于设计更有效的对抗一系列病毒性感染的疫苗。 疫苗由可使病人对潜在感染免疫的病毒蛋白组成,但疫苗内部的某些蛋白质并不促成免疫反应,因此降低了接种疫苗的效果。北京微生物流行病研究所病原微生物与生物安全国家重点实验室周育森、美国明尼苏达大学医学院李放及同事,开发出了一

中国科学家有望在治疗性乙肝疫苗领域取得新突破

这一临床实验进一步展示了皮卡技术平台广阔的应用前景,我们期待着这一核心技术带来更多创新型生物制品的开发。